Enliven Therapeutics, Inc. — Form D

Enliven Therapeutics, Inc. of BOULDER, CO, a company, filed a Form D exempt-offering notice with the SEC on 2024-04-03. The offering totals $90.0M, of which $90.0M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (30)

Showing 25 of 30 people.

NameRoleLocation
Rahul P BallalDirectorBoulder, CO
Jake P BauerDirectorBoulder, CO
Mika P DerynckDirectorBoulder, CO
Rishi P GuptaDirectorBoulder, CO
Richard P HeymanDirectorBoulder, CO
Samuel KintzDirectorBoulder, CO
Joseph P LyssikatosDirectorBoulder, CO
Andrew P PhillipsDirectorBoulder, CO
Helen P CollinsExecutive OfficerBoulder, CO
Benjamin P HohlExecutive OfficerBoulder, CO
Samuel KintzExecutive OfficerBoulder, CO
Joseph P LyssikatosExecutive OfficerBoulder, CO
Anish P PatelExecutive OfficerBoulder, CO
Rahul BallalDirectorBoston, MA
Rahul BallalExecutive OfficerBoston, MA
David G BonitaDirectorCAMBRIDGE, MA
Christoph M AdamsDirectorCAMBRIDGE, MA
Christoph M AdamsExecutive OfficerCAMBRIDGE, MA
Barbara G DaltonDirectorCAMBRIDGE, MA
James G McArthurDirectorCAMBRIDGE, MA
James G McArthurExecutive OfficerCAMBRIDGE, MA
David G MottDirectorCAMBRIDGE, MA
Carl G GoldfischerDirectorCAMBRIDGE, MA
Mark G ChinDirectorCAMBRIDGE, MA
Mette Kirstine AggerDirectorCAMBRIDGE, MA

Other filings by this issuer (2)

FiledFormOfferingSold
2019-03-29D$63.0M$44.1M
2016-04-21D$31.0M$6.0M

More